source
- Capricor to submit additional data to FDA after negative advisory committee vote on Duchenne therapyCapricor Therapeutics announced it will request the FDA to review new data and analyses for its experimental treatment for Duchenne muscular dystrophy. The move follows a recent negative vote from…
- Abcuro raises $66 million to launch Phase 3 trial in muscle-weakening disease after earlier setbackAbcuro announced it has secured $66 million in financing to support a Phase 3 clinical study targeting a muscle-weakening condition. The funding comes after the company previously reported that it…